Companies invest heavily in data but struggle to extract actionable insights. Different business units use disparate data sets, leading to conflicting signals and preventing cohesive, enterprise-wide commercial strategies. The goal is to find the "signal" in the "noise."
A MedTech company facing declining orders successfully boosted product utilization by focusing on a secondary, underutilized clinical indication. This data-driven strategy realigned sales and marketing efforts, uncovered an untapped market, and educated the sales team on a new value proposition.
Early-stage MedTech companies often have a limited, narrow understanding of their market size and product-market fit. Their intense focus on product development and regulatory hurdles causes them to neglect crucial commercialization planning, creating a major strategy gap post-approval.
The site of care for new medical technologies can change with surprising speed. For example, pulse field ablation procedures moved to ambulatory surgery centers (ASCs) within their first year on the market, a pivot many large companies did not anticipate, impacting reimbursement and sales strategies.
A comprehensive go-to-market plan requires more than direct sales or GPO contracts. Companies must develop specific approaches for different channels, including direct contracting with Integrated Delivery Networks (IDNs), using distributors for fragmented markets like ASCs, and forming strategic partnerships.
Emerging MedTech companies often view Group Purchasing Organization (GPO) agreements as a silver bullet for market access. However, these contracts require significant post-agreement effort and may be more effective as a later-stage strategy after a company has established itself through other channels.